We maintain BUY on PSP with TP of Rs 639/sh (18x Mar-20E EPS). PSPs 4QFY18 revenue was in-line with our estimates of Rs 2.6bn. Higher than expected EBITDA margins led to EBIDTA/PAT beat of 25.5/23.3%. Balance sheet continues to remain healthy with net cash/equity of 0.7x.